<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612413</url>
  </required_header>
  <id_info>
    <org_study_id>ENX-CL-02-002</org_study_id>
    <nct_id>NCT04612413</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enlivex Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enlivex Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II, multi-center (approximately 10 sites in Israel), randomized, placebo-controlled,&#xD;
      dose- finding study comparing the efficacy, safety and tolerability of different dosing&#xD;
      regimens of Allocetra-OTS, in up to 160 adult sepsis patients with organ sysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 160 eligible patients will be allocated in a 1:1:1:1 ratio between the 4 cohorts (up to&#xD;
      40 patients in each cohort). Randomization will be in a double blinding fashion which will be&#xD;
      kept until Day 4 followed by a single blinding until the end of the study.&#xD;
&#xD;
      Randomization will be stratified by screening Sequential Organ Failure Assessment (SOFA)&#xD;
      score (2-6 vs. 7-9).&#xD;
&#xD;
      Patients will be followed over 28 days for efficacy and continue safety follow up of 12&#xD;
      months from IP administration.&#xD;
&#xD;
      Patients participating in this study, regardless if hospitalized or discharged, will be&#xD;
      followed daily through Day 7 (inclusive, short-term follow-up), then on Days 10 (only for&#xD;
      patients receiving 2nd dose), Day 14, and Day 28 (medium-term follow-up), , and then at 3&#xD;
      months, 6 months and 12 months (long-term safety follow-up).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Up to 160 patients will be allocated in a 1:1:1:1 ratio between the 4 cohorts :&#xD;
Placebo Single Intravenous (IV) dose of Allocetra-OTS, 5x109 cells Single IV dose of Allocetra-OTS, 10x109 cells Single or two IV doses of Allocetra-OTS, 10x109 cells in each dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomization will be in a double blinding fashion which will be kept until study Day 4 followed by a single blinding until the end of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the safety of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>Number and severity of AEs and SAEs throughout 28 days follow up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the efficacy of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>Change from baseline in SOFA score throughout 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>Vasopressor-free days over 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients.</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator-free days over 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>Days without renal replacement therapy (dialysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>Time in ICU and time in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days with creatinine ≤ Baseline levels +20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause mortality at Day 28 following first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients</measure>
    <time_frame>28 days</time_frame>
    <description>Changes in CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess long term safety follow up</measure>
    <time_frame>12 months</time_frame>
    <description>Number and severity of AEs and Serious Adverse Events (SAEs) throughout 12 months follow up period</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Sepsis</condition>
  <condition>Community-acquired Pneumonia</condition>
  <condition>Organ Dysfunction Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>375 ml Ringer's lactate solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of Allocetra-OTS contain 5x10^9 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of Allocetra-OTS contain 10x10^9 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single or two IV doses of Allocetra-OTS contain 10x10^9 cells in each dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLOCETRA-OTS</intervention_name>
    <description>The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Cell based therapy, apoptotic cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ringer's Lactate Solution</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥45 years and ≤85 years of age.&#xD;
&#xD;
          -  Suspected, presumed or documented community-acquired pneumonia by imaging.&#xD;
&#xD;
          -  Treatment with antibiotics after at least one course for the suspected infection.&#xD;
&#xD;
          -  Meets Sepsis 3 criteria: the presence of organ dysfunction as identified by a total&#xD;
             SOFA score ≥2 points above pre-admission SOFA.&#xD;
&#xD;
          -  Has at least one respiratory SOFA score and at least one additional SOFA in any other&#xD;
             organ.&#xD;
&#xD;
          -  Signed written informed consent by the patient, or his/her legal guardian or delayed&#xD;
             patient consent (based on MOH guidelines and local Ethics Committee (EC) approval).&#xD;
&#xD;
          -  Child-bearing potential Females must not be lactating or pregnant at Screening, as&#xD;
             documented by a negative Beta-Human Chorionic Gonadotropin (ß-hCG) or Human Chorionic&#xD;
             Gonadotropin (hCG) blood test.&#xD;
&#xD;
          -  Women of child-bearing potential or males whose partners are women of child-bearing&#xD;
             potential, use an effective method of contraception throughout the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sepsis due to infection other than lung infection, or sepsis patients where site of&#xD;
             infection is unclear or unknown&#xD;
&#xD;
          -  On chronic dialysis.&#xD;
&#xD;
          -  Invasive ventilated patient with PaO2/FiO2 &lt; 100 mmHg&#xD;
&#xD;
          -  Weight &lt;50 kg or &gt;120 kg or Body Mass Index (BMI) &gt;40 kg/m2.&#xD;
&#xD;
          -  SOFA score ≥ 10 at screening (Day -1).&#xD;
&#xD;
          -  Septic shock defined by persisting hypotension requiring vasopressors to maintain MAP&#xD;
             ≥65 mmHg and having a serum lactate level &gt;2 mmol/L (18 mg/dL) despite adequate volume&#xD;
             resuscitation at screening and on Day 1 prior to IP administration.&#xD;
&#xD;
          -  Surgical intervention, plan for surgical intervention (not including percutaneous&#xD;
             procedure such as chest drain), or hospitalization within 30 days prior to diagnosis&#xD;
             of sepsis.&#xD;
&#xD;
          -  A known malignancy that is progressing or has required active treatment within the&#xD;
             past 3 months.&#xD;
&#xD;
          -  Patient with end-stage disease (unrelated to sepsis) defined as patients who prior to&#xD;
             the current hospitalization are expected to live &lt; 6 months (as assessed by the study&#xD;
             physician).&#xD;
&#xD;
          -  Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or chronic&#xD;
             viral infections, such as, Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV), Human&#xD;
             Immunodeficiency Virus (HIV) or other chronic infections.&#xD;
&#xD;
          -  Chronic respiratory disease requiring home oxygen therapy on a regular basis for &gt; 6&#xD;
             h/day.&#xD;
&#xD;
          -  Known active upper Gastrointestinal (GI) tract ulceration or hepatic dysfunction&#xD;
             including but not limited to biopsy-proven cirrhosis; End-stage cirrhosis (Child Pugh&#xD;
             Class C); portal hypertension; episodes of past upper GI bleeding attributed to portal&#xD;
             hypertension; or prior episodes of hepatic failure, encephalopathy, or coma.&#xD;
&#xD;
          -  Known New York Heart Association (NYHA) class IV heart failure or unstable angina,&#xD;
             ventricular arrhythmias, active ischemic heart disease, or myocardial infarction&#xD;
             within six months prior to diagnosis of sepsis.&#xD;
&#xD;
          -  Known immunocompromised state or medications known to be immunosuppressive.&#xD;
&#xD;
          -  Organ allograft or previous history of stem cell transplantation.&#xD;
&#xD;
          -  Participation in an interventional investigational study within 30 days prior to&#xD;
             diagnosis of sepsis.&#xD;
&#xD;
          -  Likely to be non-compliant or uncooperative during the study (e.g. substance abuse&#xD;
             such as drug or alcohol abuse, uncontrolled psychiatric disorder or any chronic&#xD;
             condition that may interfere with study conduct).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Singer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin medical center, Belinson Campus, Petah Tiqwa Isarel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Odelia Ben Shitrit, MBA</last_name>
    <phone>972-548887609</phone>
    <email>odelia@enlivexpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naama Kama</last_name>
    <phone>972523466908</phone>
    <email>naama@enlivexpharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esti Deutsch, SC</last_name>
      <phone>972-54-7488206</phone>
      <email>estid1@hadassah.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

